Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$0.92 USD
-0.03 (-2.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.92 0.00 (-0.42%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
ONCY 0.92 -0.03(-2.75%)
Will ONCY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ONCY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ONCY
Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
ONCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Novartis (NVS) to Report Q1 Earnings: What to Expect?
After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)
Other News for ONCY
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
Buy Rating Affirmed for Oncolytics Biotech on Strong Phase 2 Results and Commercial Potential
Oncolytics price target raised by C$0.50 at Raymond James, here's why
Oncolytics Phase 2 breast cancer data 'compelling, says H.C. Wainwright
Oncolytics reports favorable results for pelareorep in breast cancer study